Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

Revelation Biosciences, Inc. (NASDAQ:REVB), a clinical-stage life sciences company dedicated to rebalancing inflammation for improved health outcomes, has successfully closed a public offering, raising approximately $4 million in gross proceeds.

The offering included 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares, all priced at $1.10 per share and warrant. The warrants, exercisable upon shareholder approval, will remain valid for five years from their initial exercise date. Roth Capital Partners served as the sole placement agent for the transaction.

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

A female doctor using the latest healthcare IT technology in her medical practice.

Revelation Biosciences, Inc. (NASDAQ:REVB) plans to use the net proceeds to advance its clinical and preclinical programs. Key initiatives include completing its ongoing Phase 1b clinical trial, manufacturing clinical drug supplies, conducting additional preclinical studies for multiple indications, developing new products and therapies, and supporting general corporate operations.

While we acknowledge the potential of REVB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than AMZN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.